- Published on
KembaraXtra-Emergency and Acute Medicine: Hydatidiform Mole
Basics
Description Hydatidiform mole is a noninvasive, localized tumor arising from trophoblastic tissue and may be associated with malignancy. Twinning with a normal pregnancy is possible but carries a higher risk of persistent maternal disease and metastasis, although a normal infant may occasionally result. Complete mole occurs in ~1/1,500 pregnancies, with no fetal tissue, diffuse chorionic villi swelling, and diffuse trophoblastic hyperplasia; malignancy develops in 15–20% (commonly lung). Genetics are typically 46,XX (90%) or 46,XY (10%) with paternal-only DNA due to fertilization of an enucleated ovum by two sperm or duplication of a haploid sperm. Partial mole occurs in ~1/750 pregnancies, often with fetal or embryonic tissue, focal villous swelling, and focal trophoblastic hyperplasia; malignancy risk is 4–12%. Genetics are usually triploid (69XXX, 69XXY, rarely 69XYY) with both maternal and paternal DNA.
Etiology Largely unknown. Risk factors include extremes of maternal age (>35 years with 5–10× risk; <20 years), prior molar pregnancy (1–2% recurrence), higher prevalence in Asian and Latin American regions, dietary deficiency of animal fat and vitamin A, smoking (>15 cigarettes/day), maternal blood types AB/A/B, infertility or nulliparity, and occurrence in ~1 of 600 therapeutic abortions.
Diagnosis
Signs and symptoms Usually exaggerated pregnancy symptoms. Complete mole commonly presents with painless vaginal bleeding (97%) described as “prune juice,” passage of grapelike vesicles, hyperemesis from high β-hCG, preeclampsia (27%), hyperthyroidism (7%), and acute respiratory distress (2%) from trophoblastic emboli or related cardiopulmonary effects. Partial mole often resembles threatened or spontaneous abortion with vaginal bleeding, possible fetal heart tones, and later presentation.
History Missed menses, positive pregnancy test, nausea, vomiting, vaginal bleeding.
Physical exam Uterine size–date discrepancy in 50–66% (larger in complete, smaller in partial). Ovarian enlargement with bilateral theca lutein cysts is common in complete moles.
Essential workup
Laboratory β-hCG (often >100,000 mIU/mL in complete moles; lower in partial; >40,000 mIU/mL indicates poorer prognosis), blood type/Rh and cross-match, CBC, coagulation profile, electrolytes with BUN/creatinine, LFTs, TSH/free T4 if hyperthyroidism suspected, urinalysis for proteinuria.
Imaging
Ultrasound shows a “snowstorm” pattern with absent fetus and no amniotic fluid in complete moles and a “Swiss-cheese” placental appearance with possible fetus in partial moles. Chest X-ray assesses pulmonary edema and metastatic disease.
Pathology
All products of conception require histology. Complete moles show edematous villi with diffuse trophoblastic hyperplasia; partial moles show fetal tissue, vessels, amnion, and edematous villi.
Differential diagnosis
Threatened, missed, or incomplete abortion; ectopic pregnancy; hyperthyroidism; hyperemesis gravidarum; hypertension and preeclampsia.
Treatment
Prehospital Secure airway, provide oxygen, establish IV access, treat seizures with benzodiazepines, and save passed tissue.
Initial stabilization IV access, cardiac monitoring, and blood preparation if evacuation is planned.
Emergency department management Intubate for respiratory distress; give β-blockers before evacuation for hyperthyroidism; manage preeclampsia/eclampsia with benzodiazepines and magnesium sulfate and control blood pressure with hydralazine or labetalol; transfuse blood products for coagulopathy; administer Rho(D) immune globulin; perform suction curettage (fertility-sparing and curative in ~80%) with oxytocin; consider chemoprophylaxis only in selected high-risk cases with reliable follow-up; consider hysterectomy for older patients, those not desiring fertility, or high-risk disease.
Follow-up and disposition
Admission criteria Uterine size >16 weeks, clinical preeclampsia/hyperthyroidism/respiratory distress, hemodynamic instability, partial mole, or hysterectomy.
Discharge criteria Uncomplicated curettage of a small, low-risk mole with reliable follow-up.
Follow-up recommendations Close OB-GYN follow-up with serial β-hCG weekly for ≥4 weeks then monthly until undetectable; any rise prompts evaluation for metastasis. Use contraception and avoid pregnancy for 12 months; perform early ultrasound in future pregnancies. Recurrence risk is 1–1.5% after one mole and up to 20% after two.
Pearls and pitfalls Diagnosis may be missed with apparent normal pregnancy, preeclampsia before 24 weeks, or severe hyperemesis. Strict β-hCG follow-up is essential; up to 20% may develop malignancy if not monitored.
Basics
Description Hydatidiform mole is a noninvasive, localized tumor arising from trophoblastic tissue and may be associated with malignancy. Twinning with a normal pregnancy is possible but carries a higher risk of persistent maternal disease and metastasis, although a normal infant may occasionally result. Complete mole occurs in ~1/1,500 pregnancies, with no fetal tissue, diffuse chorionic villi swelling, and diffuse trophoblastic hyperplasia; malignancy develops in 15–20% (commonly lung). Genetics are typically 46,XX (90%) or 46,XY (10%) with paternal-only DNA due to fertilization of an enucleated ovum by two sperm or duplication of a haploid sperm. Partial mole occurs in ~1/750 pregnancies, often with fetal or embryonic tissue, focal villous swelling, and focal trophoblastic hyperplasia; malignancy risk is 4–12%. Genetics are usually triploid (69XXX, 69XXY, rarely 69XYY) with both maternal and paternal DNA.
Etiology Largely unknown. Risk factors include extremes of maternal age (>35 years with 5–10× risk; <20 years), prior molar pregnancy (1–2% recurrence), higher prevalence in Asian and Latin American regions, dietary deficiency of animal fat and vitamin A, smoking (>15 cigarettes/day), maternal blood types AB/A/B, infertility or nulliparity, and occurrence in ~1 of 600 therapeutic abortions.
Diagnosis
Signs and symptoms Usually exaggerated pregnancy symptoms. Complete mole commonly presents with painless vaginal bleeding (97%) described as “prune juice,” passage of grapelike vesicles, hyperemesis from high β-hCG, preeclampsia (27%), hyperthyroidism (7%), and acute respiratory distress (2%) from trophoblastic emboli or related cardiopulmonary effects. Partial mole often resembles threatened or spontaneous abortion with vaginal bleeding, possible fetal heart tones, and later presentation.
History Missed menses, positive pregnancy test, nausea, vomiting, vaginal bleeding.
Physical exam Uterine size–date discrepancy in 50–66% (larger in complete, smaller in partial). Ovarian enlargement with bilateral theca lutein cysts is common in complete moles.
Essential workup
Laboratory β-hCG (often >100,000 mIU/mL in complete moles; lower in partial; >40,000 mIU/mL indicates poorer prognosis), blood type/Rh and cross-match, CBC, coagulation profile, electrolytes with BUN/creatinine, LFTs, TSH/free T4 if hyperthyroidism suspected, urinalysis for proteinuria.
Imaging
Ultrasound shows a “snowstorm” pattern with absent fetus and no amniotic fluid in complete moles and a “Swiss-cheese” placental appearance with possible fetus in partial moles. Chest X-ray assesses pulmonary edema and metastatic disease.
Pathology
All products of conception require histology. Complete moles show edematous villi with diffuse trophoblastic hyperplasia; partial moles show fetal tissue, vessels, amnion, and edematous villi.
Differential diagnosis
Threatened, missed, or incomplete abortion; ectopic pregnancy; hyperthyroidism; hyperemesis gravidarum; hypertension and preeclampsia.
Treatment
Prehospital Secure airway, provide oxygen, establish IV access, treat seizures with benzodiazepines, and save passed tissue.
Initial stabilization IV access, cardiac monitoring, and blood preparation if evacuation is planned.
Emergency department management Intubate for respiratory distress; give β-blockers before evacuation for hyperthyroidism; manage preeclampsia/eclampsia with benzodiazepines and magnesium sulfate and control blood pressure with hydralazine or labetalol; transfuse blood products for coagulopathy; administer Rho(D) immune globulin; perform suction curettage (fertility-sparing and curative in ~80%) with oxytocin; consider chemoprophylaxis only in selected high-risk cases with reliable follow-up; consider hysterectomy for older patients, those not desiring fertility, or high-risk disease.
Follow-up and disposition
Admission criteria Uterine size >16 weeks, clinical preeclampsia/hyperthyroidism/respiratory distress, hemodynamic instability, partial mole, or hysterectomy.
Discharge criteria Uncomplicated curettage of a small, low-risk mole with reliable follow-up.
Follow-up recommendations Close OB-GYN follow-up with serial β-hCG weekly for ≥4 weeks then monthly until undetectable; any rise prompts evaluation for metastasis. Use contraception and avoid pregnancy for 12 months; perform early ultrasound in future pregnancies. Recurrence risk is 1–1.5% after one mole and up to 20% after two.
Pearls and pitfalls Diagnosis may be missed with apparent normal pregnancy, preeclampsia before 24 weeks, or severe hyperemesis. Strict β-hCG follow-up is essential; up to 20% may develop malignancy if not monitored.
0 Comments
